Predictors of distant metastasis in human papillomavirus–associated oropharyngeal cancer

Weller, Michael; Ward, Matthew C.; Berriochoa, Camille A.; Reddy, Chandana A.; Trosman, Samuel J.; Greskovich, J.F.; Nwizu, T.; Burkey, Brian B.; Adelstein, David J.; Koyfman, Shlomo A.

doi:10.1002/hed.24711

Cited by 31 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent analysis of predictors of distant disease from the Cleveland Clinic included 310 HPV+ORO patients with stage III to IVb disease (AJCC, 7th edition) who were treated with either cisplatin‐based chemoradiation or cetuximab with concurrent external radiation . The determination of the HPV status was performed with either in situ hybridization for HPV DNA or p16 staining.…”

Section: Discussionmentioning

confidence: 99%

Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx

Beitler

Switchenko

Dignam

et al. 2018

Cancer

View full text Add to dashboard Cite

BACKGROUND:With an expectation of excellent locoregional control, ongoing efforts to de-intensify therapy for patients with human papillomavirus-associated squamous cell oropharyngeal cancer necessitate a better understanding of the metastatic risk for patients with this disease. The objective of this study was to determine what factors affect the risk of metastases in patients with squamous cell cancers of the oropharynx. METHODS: Under a shared use agreement, 547 patients from Radiation Therapy Oncology Group 0129 and 0522 with nonmetastatic oropharyngeal squamous cell cancers who had a known p16 status and smoking status were analyzed to assess the association of clinical features with the development of distant metastases. The analyzed factors included the p16 status, sex, T stage, N stage, age, and smoking history. RESULTS: A multivariate analysis of 547 patients with a median follow-up of 4.8 years revealed that an age ≥ 50 years (hazard ratio [HR], 3.28; P = .003), smoking for more than 0 pack-years (HR, 3.09; P < .001), N3 disease (HR, 2.64; P < .001), T4 disease (HR, 1.63; P = .030), and a negative p16 status (HR, 1.60; P = .044) were all factors associated with an increased risk of distant disease. CONCLUSIONS: Age, smoking, N3 disease, T4 disease, and a negative p16 status were associated with the development of distant metastases in patients with squamous cell cancers of the oropharynx treated definitively with concurrent chemoradiation. Cancer 2019;125:704-711.

show abstract

Section: Discussionmentioning

confidence: 99%

Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx

Beitler

Switchenko

Dignam

et al. 2018

Cancer

View full text Add to dashboard Cite

show abstract

“…The underlying molecular reasons for this difference are not entirely clear. However, approximately 10% of all HPV+ HNSCC patients still succumb to their disease [11]. Identification of prognostic markers predicting favorable survival outcomes in patients could allow for treatment deintensification, thereby avoiding potential lifelong complications from unnecessarily aggressive treatments.…”

Section: Introductionmentioning

confidence: 99%

Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers

Prusinkiewicz

Gameiro

Ghasemi

et al. 2020

Cancers

View full text Add to dashboard Cite

Human papillomavirus (HPV) causes an increasing number of head and neck squamous cell carcinomas (HNSCCs). Altered metabolism contributes to patient prognosis, but the impact of HPV status on HNSCC metabolism remains relatively uncharacterized. We hypothesize that metabolism-related gene expression differences unique to HPV-positive HNSCC influences patient survival. The Cancer Genome Atlas RNA-seq data from primary HNSCC patient samples were categorized as 73 HPV-positive, 442 HPV-negative, and 43 normal-adjacent control tissues. We analyzed 229 metabolic genes and identified numerous differentially expressed genes between HPV-positive and negative HNSCC patients. HPV-positive carcinomas exhibited lower expression levels of genes involved in glycolysis and higher levels of genes involved in the tricarboxylic acid cycle, oxidative phosphorylation, and β-oxidation than the HPV-negative carcinomas. Importantly, reduced expression of the metabolism-related genes SDHC, COX7A1, COX16, COX17, ELOVL6, GOT2, and SLC16A2 were correlated with improved patient survival only in the HPV-positive group. This work suggests that specific transcriptional alterations in metabolic genes may serve as predictive biomarkers of patient outcome and identifies potential targets for novel therapeutic intervention in HPV-positive head and neck cancers.

show abstract

“…In contrast, tobacco smoking is a well‐established carcinogen and the primary risk factor for HPV(−) OPSCC worldwide . In addition to increasing the risk of developing OPSCC, smoking has been associated with treatment response, risk of distant metastasis, risk of additional primary cancers, and overall survival (OS) . However, these trends have largely been observed among patients with human papillomavirus (HPV)‐negative OPSCC …”

Section: Introductionmentioning

confidence: 99%

Impact of active smoking on outcomes in HPV+ oropharyngeal cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: The role of smoking among patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is unclear.Methods: A retrospective cohort study of patients with HPV(+) OPSCC from 2001 to 2015 at a tertiary-care institution was conducted. The primary outcome was overall survival (OS). Results: Among 484 included patients, 94 (19.4%) were active smokers, 226 (46.7%) were former smokers, and 164 (33.9%) never smoked. Among active smokers, 82 patients (87.2%) had a ≥10 pack-year and 69 (73.4%) had a ≥20 pack-year smoking history. After adjusting for covariates, active smoking was a significant predictor of inferior OS (HR 2.28, P < .001) and PFS (HR 2.26, P < .001). When including pack-years as the covariate, ≥20 packyears predicted a decreased effect-size for inferior OS and PFS. Conclusions: For patients with HPV(+) OPSCC, active smoking at diagnosis is the most powerful covariate capturing smoking history to predict OS and PFS. K E Y W O R D S human papillomavirus, oropharyngeal cancer, overall survival, pack-years, smoking status

show abstract

Predictors of distant metastasis in human papillomavirus–associated oropharyngeal cancer

Cited by 31 publications

References 29 publications

Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx

Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx

Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers

Impact of active smoking on outcomes in HPV+ oropharyngeal cancer

Contact Info

Product

Resources

About